ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
Results from a post-hoc analysis of JAVELIN-Renal 101 in patients [...]
Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
It has just been announced that the avelumab plus axitinib [...]
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
The Food and Drug Administration (FDA) in the United States [...]
The results from the following study were presented at the [...]
The following article from Practice Update discusses the JAVELIN Renal [...]
The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr [...]